Open Interest and Volume Dynamics
The latest data reveals that Aurobindo Pharma’s open interest (OI) in derivatives rose sharply from 55,954 contracts to 67,931, an increase of 11,977 contracts or 21.41%. This surge in OI was accompanied by a futures volume of 38,441 contracts, reflecting robust trading activity. The combined futures and options value stands at approximately ₹12,307 crores, underscoring the stock’s liquidity and investor interest.
Such a pronounced increase in open interest typically indicates fresh positions being established rather than existing ones being squared off. This suggests that traders are actively repositioning themselves, possibly anticipating a directional move in the stock. The underlying price of ₹1,276 remains just 3.41% shy of its 52-week high of ₹1,319.8, reinforcing the stock’s resilience despite recent volatility.
Price Performance and Sector Context
On 23 Mar 2026, Aurobindo Pharma’s share price declined by 0.98%, marginally underperforming its one-day return of -1.17%. However, this was still a relative outperformance compared to the Pharmaceuticals & Biotechnology sector, which fell by 3.21%, and the broader Sensex, which declined 2.51%. The stock’s ability to trade above all key moving averages—5-day, 20-day, 50-day, 100-day, and 200-day—signals sustained bullish momentum despite the minor pullback.
Investor participation has also intensified, with delivery volumes rising 18.21% to 6.48 lakh shares on 20 Mar compared to the five-day average. This increase in delivery volume indicates genuine buying interest rather than speculative intraday trading, which could support the stock’s price stability in the near term.
Transformation in full progress! This Micro Cap from Auto Ancillary just achieved sustainable profitability after tough times. Be early to witness this powerful comeback story!
- - Sustainable profitability reached
- - Post-turnaround strength
- - Comeback story unfolding
Market Positioning and Directional Bets
The surge in open interest alongside rising volumes suggests that market participants are actively repositioning their bets on Aurobindo Pharma. Given the stock’s proximity to its 52-week high and its outperformance relative to the sector, it is plausible that traders are taking bullish stances, expecting further upside potential.
However, the slight price decline and the stock’s current Mojo Grade downgrade from Buy to Hold (as of 16 Mar 2026) with a Mojo Score of 68.0 indicate some caution among analysts. The downgrade reflects a reassessment of the stock’s near-term growth prospects and risk profile amid evolving market conditions.
Investors should note that the pharmaceutical sector has been under pressure recently, with the sector index falling 3.21% on the day. Aurobindo Pharma’s relative strength in this environment may attract tactical buying, but the Hold rating suggests that investors should monitor developments closely before committing fresh capital.
Liquidity and Trading Considerations
Liquidity remains robust for Aurobindo Pharma, with the stock’s traded value supporting a trade size of approximately ₹3.13 crores based on 2% of the five-day average traded value. This level of liquidity is favourable for institutional investors and traders seeking to enter or exit positions without significant market impact.
The futures value of ₹1,20,734 lakhs and options value exceeding ₹15,209 crores highlight the extensive derivatives market activity surrounding the stock. Such active participation in derivatives markets often precedes notable price movements, as investors hedge or speculate on anticipated volatility.
Considering Aurobindo Pharma Ltd.? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this mid-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Outlook and Investor Takeaways
While the open interest surge signals renewed interest and potential directional bets on Aurobindo Pharma, investors should weigh this against the recent downgrade to Hold and the broader sector weakness. The stock’s ability to maintain levels above key moving averages and its proximity to the 52-week high are positive technical indicators, but caution is warranted given the mixed signals.
Investors with a medium-term horizon may consider monitoring the stock for confirmation of sustained buying interest and further price appreciation. Meanwhile, those with a lower risk tolerance might await clearer directional cues or a reversion to a Buy rating before increasing exposure.
Overall, Aurobindo Pharma remains a significant player in the Pharmaceuticals & Biotechnology sector with a market capitalisation of ₹74,383 crores, classified as a mid-cap stock. Its current market dynamics reflect a complex interplay of bullish positioning and cautious analyst sentiment, making it a stock to watch closely in the coming weeks.
Summary of Key Metrics:
- Open Interest: 67,931 contracts (up 21.41%)
- Futures Volume: 38,441 contracts
- Underlying Price: ₹1,276 (3.41% below 52-week high)
- Mojo Score: 68.0 (Hold rating, downgraded from Buy on 16 Mar 2026)
- Market Cap: ₹74,383 crores (Mid Cap)
- Sector Performance: -3.21% (Pharmaceuticals & Biotechnology)
- Stock 1D Return: -1.17% (outperforming sector and Sensex)
Investors should continue to analyse volume and open interest trends alongside fundamental developments to gauge the stock’s trajectory accurately.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
